Common Contracts
4 similar null contracts
ContractAugust 11th, 2017
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-419-3896 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-419-3896 This Clinical Trial Agreement (“Agreement”) is entered into as of 26/06/2017 (the “Effective Date”) by and among Thomayerova Nemocnice, a hospital with an address at Vídeňská 800, 140 59 Praha 4, Czech Republic, ID: 00064190, TIN: CZ 00064190, statecontributory organization established by the Ministry of Health of the Czech Republic, full text of foundation deed No. MZDR 17268-IV/2012 represented by doc. MUDr. Zdeněk Beneš, director (the “Institution”), doc. MUDr. Pavel Kohout, PhD., with work address at Thomayerova Nemocnice, Internal Department, pavilon B3, Vídeňská 800, 140 59 Praha 4, Czech Republic the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical
ContractEngland • March 30th, 2017
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-418-3898 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-418-3898 This Clinical Trial Agreement (“Agreement”) is entered into as of February 21, 2017 (the “Effective Date”) by and among Oblastní nemocnice Mladá Boleslav, a.s., nemocnice Středočeského kraje, a joint-stock company with an address at třída Václava Klementa 147, 29301, Mladá Boleslav, CzechRepublic, ID: 272 56 456, TIN: CZ27256456,represented by JUDr. Ladislav Řípa, director (the “Institution”), /osobní údaj/, with work address at třída Václava Klementa 147, 29301, Mladá Boleslav, Czech Republic, the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-418-3898, “Combined Phase 2b/3, Double-Blind, Randomized, Placebo- Con
ContractMarch 30th, 2017
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-418-3899 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-418-3899 This Clinical Trial Agreement (“Agreement”) is entered into as of February 21, 2017 (the “Effective Date”) by and among Oblastní nemocnice Mladá Boleslav, a.s., nemocnice Středočeského kraje, a joint-stock company with an address at třída Václava Klementa 147, 29301, Mladá Boleslav, CzechRepublic, ID: 272 56 456, TIN: CZ27256456,represented by JUDr. Ladislav Řípa, director (the “Institution”), /osobní údaj/, with work address at třída Václava Klementa 147, 29301, Mladá Boleslav, Czech Republic, the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-418-3899, “A Long-Term Extension Study to Evaluate the Safety of Filgo
ContractEngland • March 30th, 2017
CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-419-3895 SMLOUVA O KLINICKÉ STUDII PRO PROTOKOL GS-US-419-3895 This Clinical Trial Agreement (“Agreement”) is entered into as of February 21, 2017 (the “Effective Date”) by and among Oblastní nemocnice Mladá Boleslav, a.s., nemocnice Středočeského kraje, a joint-stock company with an address at třída Václava Klementa 147, 29301, Mladá Boleslav, CzechRepublic, ID: 272 56 456, TIN: CZ27256456,represented by JUDr. Ladislav Řípa, director (the “Institution”), /osobní údaj/, with work address at třída Václava Klementa 147, 29301, Mladá Boleslav, Czech Republic, the investigator for the Trial (the “Investigator”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-419-3895, “Combined Phase 3, Double-blind, Randomized, Placebo-Control
